Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 37 versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 37 versus QOLIANA.
FENTANYL-37 vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a mu-opioid receptor agonist, producing analgesia, sedation, and respiratory depression by activating G-protein coupled opioid receptors in the CNS, leading to inhibition of adenylate cyclase, decreased cAMP, and reduced neurotransmitter release.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
For opioid-naive adults, initial dose 50-100 mcg IV/IM every 1-2 hours as needed for pain; transdermal: 12-25 mcg/h applied every 72 hours for opioid-tolerant patients only. For anesthesia: 2-20 mcg/kg IV as part of balanced anesthesia.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 3–7 hours (prolonged in elderly, hepatic impairment, or with continuous infusion due to context-sensitive half-life up to 300 min).
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Renal: ~75% (as metabolites, <10% unchanged); Fecal: ~9%; Biliary: minor.
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist